0001055726-26-000008
SEC filingInovio Pharmaceuticals, Inc. reported a net loss of $84.9 million for fiscal year 2025, driven by an operating loss of $86.8 million. The company generated minimal revenue of $65,000 from collaborative arrangements, while operating expenses totaled $86.9 million, primarily consisting of research and development ($54.2 million) and general and administrative expenses ($32.7 million). The company's cash position decreased by $21.5 million during the year, ending with $14.3 million in cash and cash equivalents. Total assets stood at $74.3 million, with current assets of $61.1 million, while total liabilities were $50.2 million, resulting in stockholders' equity of $24.1 million. The company's cash burn from operations was $88.6 million, partially offset by $14.0 million from investing activities and $53.1 million from financing activities, primarily from equity issuances.
Inovio Pharmaceuticals reported a net loss of $84.9 million for fiscal year 2025, representing a significant operating loss of $86.8 million. The company generated minimal revenue of $65,000 from collaborative arrangements, while total operating expenses reached $86.9 million. Research and development expenses accounted for $54.2 million of the total operating expenses, with general and administrative expenses comprising $32.7 million. Other income items included interest income of $2.4 million, a change in fair value of common stock warrant liabilities of -$493,000, a gain on investment in affiliated entity of $490,000, net unrealized gain on available-for-sale equity securities of $1.1 million, and other expense, net of -$2.6 million. The company reported basic and diluted net loss per share of $2.00, based on weighted average shares outstanding of 46.9 million.
The company reported only $65,000 in revenue from collaborative arrangements for fiscal year 2025. No other revenue sources were disclosed in the financial data. The minimal revenue reflects the company's pre-commercial stage of development, with no product sales reported. The company's business model appears focused on research and development activities rather than commercial operations at this stage.
Given the minimal revenue of $65,000 and operating loss of $86.8 million, the company operates at a significant loss margin. The cost structure is dominated by research and development expenses of $54.2 million, representing approximately 62% of total operating expenses. General and administrative expenses of $32.7 million account for the remaining 38% of operating expenses. The company's accumulated deficit reached $1.82 billion as of December 31, 2025, reflecting the cumulative losses from ongoing research and development activities.
The company used $88.6 million in cash from operating activities during fiscal year 2025. Investing activities provided $14.0 million in cash, primarily from proceeds from sale of investments ($14.3 million) and proceeds from maturity of investments ($5.0 million), partially offset by purchases of investments ($4.9 million). Financing activities provided $53.1 million in cash, mainly from proceeds from issuance of common stock, net of issuance costs ($34.9 million) and proceeds from warrant exercises ($1.3 million). The net decrease in cash and cash equivalents was $21.5 million, ending the period with $14.3 million. Total assets were $74.3 million, including current assets of $61.1 million (cash and cash equivalents of $44.3 million, short-term investments of $14.2 million, and prepaid expenses of $2.6 million). Total liabilities were $50.2 million, including common stock warrant liabilities of $29.1 million and operating lease liabilities of $9.3 million. Stockholders' equity was $24.1 million.
The filing contains forward-looking statements regarding the company's business, financial condition, results of operations and prospects, but no specific financial guidance or projections are provided. The company acknowledges that forward-looking statements are inherently subject to risks and uncertainties. Risk factors mentioned include cybersecurity threats that could lead to regulatory investigations, litigation, fines, business disruptions, reputational harm, and loss of revenue. The board's audit committee oversees cybersecurity risk management processes, with the Vice President of IT and CFO responsible for implementation and incident response. The company's continued operations depend on its ability to manage research and development expenses while securing additional financing through equity issuances or other means.